SCHEMBL307994

SCHEMBL307994

[NH]C(=O)c1ccc[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL371069 0.79 TSHR (0.54)
SCHEMBL5320628 0.79 TSHR (0.54)
SCHEMBL10141203 0.77
SCHEMBL21114388 0.77 TSHR (0.57)
SCHEMBL28298 0.77
SCHEMBL10141202 0.77
SCHEMBL302811 0.77
Water SCHEMBL5567597 0.75
SCHEMBL17363100 0.75
SCHEMBL10507082 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3906031-A1 CANCER TREATMENT USING MULTI-TARGETED KINASE INHIBITOR IN COMBINATION OF PROTEIN KINASE BIOMARKERS Zhejiang Crownmab Biotech Co. Ltd. (CN) 2021-11-10 EP claimed
CN-113498341-A Cancer treatment using multi-target kinase inhibitors in combination with protein kinase biomarkers 浙江冠科美博生物科技有限公司 2021-10-12 CN claimed
WO-2020140927-A1 CANCER TREATMENT USING MULTI-TARGETED KINASE INHIBITOR IN COMBINATION OF PROTEIN KINASE BIOMARKERS CROWNMAB BIOTECH INC. (CN) 2020-07-09 WO claimed
EP-2864289-B1 CYCLOPROPANECARBOXAMIDO-SUBSTITUTED AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS CB THERAPEUTICS INC (KY) 2018-04-11 EP claimed
US-9359338-B2 Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents CROWN BIOSCIENCE INC. (TAIWAN) (TW) 2016-06-07 US claimed
US-20150197511-A1 CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS APOLLOMICS INC. 2015-07-16 US claimed
EP-2864289-A1 CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS Crown Bioscience Inc. (Taiwan) (CN) 2015-04-29 EP claimed
WO-2014000418-A1 CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS CROWN BIOSCIENCE INC. (TAICANG) (CN) 2014-01-03 WO claimed
EP-1730152-B1 TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME MITSUBISHI TANABE PHARMA CORP (JP) 2012-05-02 EP claimed
US-20110190295-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET SIGNALING The Govt of the U.S.A., as rep.by the Sec.Dept of Hlth. and Human Svcs., Natl Institutes of Health (US) 2011-08-04 US claimed
US-20070032485-A1 Tetrahydronaphthyridine derivatives and a process for preparing the same TANABE SEIYAKU CO., LTD. 2007-02-08 US claimed
EP-1174151-B1 THERAPEUTIC TREATMENT OF EOSINOPHILIA USING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT DAIICHI ASUBIO PHARMA CO LTD (JP) 2007-01-24 EP claimed
EP-1732924-A2 TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS TANABE SEIYAKU CO., LTD. (JP) 2006-12-20 EP claimed
EP-1730152-A2 TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME TANABE SEIYAKU CO., LTD. (JP) 2006-12-13 EP claimed
WO-2005095395-A2 TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS TANABE SEIYAKU CO., LTD. (JP) 2005-10-13 WO claimed
WO-2005095409-A2 TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME TANABE SEIYAKU CO., LTD. (JP) 2005-10-13 WO claimed
US-6677344-B2 Chymase inhibitor for the treatment of eosinophilia DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2004-01-13 US claimed
US-6500835-B2 FOR PROPHYLAXIS AND THERAPY OF FIBROSIS INVOLVING EXTRACELLULAR MATRIX DYSBOLISM HAVING A CHYMASE INHIBITOR AS AN EFFECTIVE INGREDIENT; SIDE EFFECT REDUCTION SUNTORY LIMITED (JP) 2002-12-31 US claimed
US-5801181-A Amino alcohol substituted cyclic compounds CELL THERAPEUTICS, INC. (US) 1998-09-01 US claimed
WO-1995003298-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS DOPAMINE RECEPTOR ANTAGONIST, 5-HT RECEPTOR AGONIST OR α1 RECEPTOR ANTAGONIST FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-02-02 WO claimed